BBB Shuttle Compounds for Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic compounds targeting the brain face significant challenges due to the blood-brain barrier (BBB), with over 98% of potential drugs failing to cross, hindering treatments for neurodegenerative diseases, brain cancer, psychiatric disorders, and other central nervous system conditions.
Innovation Solution
Development of 'shuttle' compounds that are biodegradable and biocompatible, made of amino acids, capable of crossing the BBB through passive diffusion, allowing the transport of substances that cannot cross on their own, including diagnostic agents and pharmaceutical ingredients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs are used to treat brain conditions, then therapeutic effect is achieved, but the drugs cannot cross the blood-brain barrier
Solution Approach 1:
The patent employs shuttle compounds as intermediary vehicles that carry therapeutic drugs across the blood-brain barrier. These shuttles are designed to interact with both the barrier and the cargo, facilitating transport without requiring the drug itself to have penetrating properties. The shuttle-cargo construct combines the BBB-crossing capability of the shuttle with the therapeutic activity of the drug.
Solution Approach 2:
The invention creates composite molecular structures by conjugating shuttle compounds with therapeutic agents to form shuttle-cargo constructs. This composite approach allows the combination of functional elements (BBB penetration function + therapeutic function) into a single active entity that overcomes the barrier limitation.
2Reliability
If invasive treatment methods are used to deliver drugs to the brain, then drug delivery is achieved, but patient comfort and treatment acceptance decrease
Solution Approach 1:
The shuttle compounds are designed to autonomously cross the blood-brain barrier through passive diffusion, eliminating the need for invasive procedures such as intracranial injections or surgical interventions. The system performs the delivery function automatically once administered systemically, maintaining natural physiological pathways.
3Reliability
If existing therapeutic compounds are used, then treatment effect is achieved, but severe side effects occur
Solution Approach 1:
The patent separates the delivery function from the therapeutic function by using distinct molecular components: the shuttle compound handles BBB penetration while the cargo compound provides therapeutic activity. This segmentation allows optimization of each function independently, reducing off-target effects and improving safety profiles.
Solution Approach 2:
The shuttle acts as a protective intermediary that delivers the therapeutic drug to the brain without the drug itself needing to circulate systemically at high concentrations, thereby reducing systemic side effects while maintaining effective brain targeting.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the delivery of therapeutic and diagnostic agents across the BBB, potentially transforming treatments for conditions like Parkinson's disease, HIV encephalopathy, and brain cancer by facilitating the passage of compounds like dopamine and baicalin, reducing side effects and invasive treatment methods.
Implementation Method 1
capable of crossing the BBB through passive diffusion
Data Source
AI summary
Compounds of formula (I), where R1 and R3 are H or (C1-C4)-alkyl; R2 is H or a C-radical derived from one of the known ring systems with 1-4 rings; X1 is a (C1-C6)-alkyl biradical derived from a linear or branched carbon chain; and X2 is —NH—, —NH—(CH2)1-3—COO—, —NH—(CH2)1-3—S—, or —NH—CO—(CH2)1-3—S—, are useful as blood-brain barrier shuttles (BBB). BBB shuttle-cargo constructs, the cargo being a substance susceptible to form an amide or an ester or a disulfide bound with X2 and being unable to cross the blood-brain barrier by itself, are useful as medicaments.